Dermapharm Holding SE(DE:DMP)
€38.60+0.10 (+0.26%)
DE:DMP
Dermapharm Holding SE financials statements
€38.60
At close:+0.10 (+0.26%)
Want to see DE:DMP full AI Analyst Report?
Dermapharm Holding SE (DMP) Ratios
15 Followers
Dermapharm Holding SE Ratios
DE:DMP's free cash flow for Q2 2026 was €28.55M. For the 2026 fiscal year, DE:DMP's free cash flow was decreased by €-14.94M and operating cash flow was €43.49M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.05 | 1.82 | 1.60 | 2.45 | 3.34 |
| Quick Ratio | 1.09 | 0.78 | 0.79 | 1.30 | 1.79 |
| Cash Ratio | 0.59 | 0.37 | 0.40 | 0.69 | 1.03 |
| Solvency Ratio | 0.15 | 0.14 | 0.10 | 0.27 | 0.29 |
| Operating Cash Flow Ratio | 0.53 | 0.62 | 0.56 | 1.32 | 1.61 |
| Short-Term Operating Cash Flow Coverage | 1.48 | 2.37 | 1.97 | 154.38 | 105.24 |
| Net Current Asset Value | € -800.07M | € -878.23M | € -985.13M | € -346.40M | € -387.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.48 | 0.47 | 0.50 | 0.37 | 0.41 |
| Debt-to-Equity Ratio | 1.52 | 1.62 | 2.00 | 0.97 | 1.17 |
| Debt-to-Capital Ratio | 0.60 | 0.62 | 0.67 | 0.49 | 0.54 |
| Long-Term Debt-to-Capital Ratio | 0.57 | 0.59 | 0.64 | 0.49 | 0.53 |
| Financial Leverage Ratio | 3.18 | 3.44 | 4.01 | 2.66 | 2.83 |
| Debt Service Coverage Ratio | 1.50 | 1.82 | 1.29 | 15.64 | 22.41 |
| Interest Coverage Ratio | 4.21 | 3.71 | 3.07 | 17.57 | 30.30 |
| Debt to Market Cap | 0.48 | 0.46 | 0.47 | 0.25 | 0.12 |
| Interest Debt Per Share | 20.52 | 19.28 | 21.17 | 9.85 | 10.96 |
| Net Debt to EBITDA | 2.70 | 2.67 | 3.47 | 1.11 | 1.17 |
| Profitability Margins | |||||
| Gross Profit Margin | 33.62% | 64.96% | 63.34% | 64.49% | 65.83% |
| EBIT Margin | 19.03% | 19.51% | 14.18% | 22.31% | 32.01% |
| EBITDA Margin | 26.98% | 27.18% | 23.39% | 32.18% | 37.98% |
| Operating Profit Margin | 19.03% | 18.37% | 16.11% | 23.78% | 31.65% |
| Pretax Profit Margin | 15.75% | 14.57% | 9.34% | 21.11% | 31.07% |
| Net Profit Margin | 11.37% | 9.64% | 5.49% | 13.10% | 22.23% |
| Continuous Operations Profit Margin | 11.28% | 9.46% | 5.33% | 14.26% | 22.12% |
| Net Income Per EBT | 72.16% | 66.15% | 58.84% | 62.06% | 71.54% |
| EBT Per EBIT | 82.76% | 79.29% | 57.95% | 88.76% | 98.16% |
| Return on Assets (ROA) | 6.01% | 5.47% | 2.89% | 9.50% | 14.90% |
| Return on Equity (ROE) | 19.07% | 18.83% | 11.57% | 25.25% | 42.14% |
| Return on Capital Employed (ROCE) | 11.91% | 12.37% | 10.36% | 20.39% | 23.85% |
| Return on Invested Capital (ROIC) | 7.97% | 7.65% | 5.55% | 12.45% | 16.93% |
| Return on Tangible Assets | 11.64% | 11.48% | 6.01% | 16.05% | 24.73% |
| Earnings Yield | 6.25% | 5.43% | 2.74% | 6.65% | 4.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.60 | 11.24 | 11.90 | 10.23 | 12.39 |
| Payables Turnover | 8.03 | 4.36 | 4.80 | 6.49 | 6.18 |
| Inventory Turnover | 2.35 | 1.22 | 1.30 | 1.45 | 1.34 |
| Fixed Asset Turnover | 3.66 | 3.75 | 3.43 | 4.54 | 4.24 |
| Asset Turnover | 0.53 | 0.57 | 0.53 | 0.73 | 0.67 |
| Working Capital Turnover Ratio | 3.72 | 4.70 | 4.11 | 3.02 | 2.99 |
| Cash Conversion Cycle | 147.75 | 248.68 | 235.99 | 231.96 | 242.90 |
| Days of Sales Outstanding | 38.03 | 32.46 | 30.67 | 35.67 | 29.45 |
| Days of Inventory Outstanding | 155.16 | 299.85 | 281.31 | 252.55 | 272.47 |
| Days of Payables Outstanding | 45.44 | 83.63 | 75.98 | 56.26 | 59.02 |
| Operating Cycle | 193.19 | 332.31 | 311.98 | 288.22 | 301.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.37 | 3.74 | 4.08 | 5.36 | 4.65 |
| Free Cash Flow Per Share | 2.59 | 3.03 | 3.30 | 4.63 | 3.51 |
| Dividend Paid and CapEx Coverage Ratio | 2.00 | 2.35 | 2.24 | 1.85 | 2.31 |
| Capital Expenditure Coverage Ratio | 4.31 | 5.27 | 5.28 | 7.40 | 4.09 |
| Operating Cash Flow Coverage Ratio | 0.17 | 0.21 | 0.20 | 0.56 | 0.43 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.17 | 0.19 | 0.28 | 0.27 |
| Free Cash Flow Yield | 6.58% | 7.79% | 7.80% | 12.35% | 3.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.00 | 18.41 | 36.55 | 15.05 | 22.94 |
| Price-to-Sales (P/S) Ratio | 1.82 | 1.77 | 2.01 | 1.97 | 5.10 |
| Price-to-Book (P/B) Ratio | 3.05 | 3.47 | 4.23 | 3.80 | 9.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 15.20 | 12.84 | 12.82 | 8.10 | 25.42 |
| Price-to-Operating Cash Flow Ratio | 11.67 | 10.40 | 10.39 | 7.00 | 19.20 |
| Price-to-Earnings Growth (PEG) Ratio | 0.96 | 0.22 | -0.68 | -0.42 | 0.16 |
| Enterprise Value Multiple | 9.44 | 9.20 | 12.06 | 7.24 | 14.60 |
| Enterprise Value | 2.97B | 2.95B | 3.20B | 2.39B | 5.23B |
| EV to EBITDA | 9.44 | 9.20 | 12.06 | 7.24 | 14.60 |
| EV to Sales | 2.55 | 2.50 | 2.82 | 2.33 | 5.54 |
| EV to Free Cash Flow | 21.29 | 18.10 | 18.00 | 9.56 | 27.64 |
| EV to Operating Cash Flow | 16.35 | 14.66 | 14.59 | 8.27 | 20.88 |
| Tangible Book Value Per Share | -6.79 | -8.92 | -10.74 | -0.81 | -1.11 |
| Shareholders’ Equity Per Share | 12.90 | 11.23 | 10.01 | 9.87 | 9.24 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.28 | 0.35 | 0.43 | 0.39 | 0.29 |
| Revenue Per Share | 21.64 | 21.93 | 21.09 | 19.03 | 17.51 |
| Net Income Per Share | 2.46 | 2.11 | 1.16 | 2.49 | 3.89 |
| Tax Burden | 0.72 | 0.66 | 0.59 | 0.62 | 0.72 |
| Interest Burden | 0.83 | 0.75 | 0.66 | 0.95 | 0.97 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| SG&A to Revenue | 0.07 | 0.07 | 0.02 | 0.02 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.37 | 1.17 | 3.52 | 1.33 | 0.85 |
Currency in EUR
